China-based Clover Biopharmaceuticals Ltd., (HKG: 2197) announced the completion of enrollment for the first participants in a Phase I clinical trial evaluating its SCB-1022 (RSV + hMPV) and SCB-1033 (RSV + hMPV + PIV3) respiratory combination vaccine candidates. These candidates were developed using the company’s proprietary Trimer-Tag vaccine platform.
Trial Details
The trial primarily assesses the safety, reactogenicity, and immunogenicity of the vaccines. It has recruited 192 elderly participants aged 60–85, who will be randomly administered SCB-1022 (RSV + hMPV), SCB-1033 (RSV + hMPV + PIV3), or the control vaccine SCB-1019 (RSV).
Previous Results
In October 2024, Clover Bio released Phase I clinical trial results for its unadjuvanted RSV PreF candidate vaccine (SCB-1019) in 70 elderly participants aged 60–85. A head-to-head comparison with GSK’s AS01E-adjuvanted RSV vaccine, Arexyv, showed that SCB-1019 demonstrated potentially best-in-class immunogenicity and tolerability profiles.-Fineline Info & Tech
